$2.33B in CY2024 Part D spend160K claims · 28K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Apalutamide used for?
ERLEADA is indicated for the treatment of patients with Metastatic castration-sensitive prostate cancer (mCSPC) Non-metastatic castration-resistant prostate cancer (nmCRPC) ERLEADA is an androgen r....
Is there a generic for Apalutamide?
Yes. 1 ANDAs filed at FDA, 1 generic manufacturers currently shipping.
How much does my plan pay for Apalutamide?
NADAC pricing data not currently available for this drug.
Is Apalutamide on the FDA shortage list?
No. Apalutamide is not currently on the FDA Drug Shortage Database.
5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (3 approvals on file) · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.